Acute kidney injury following treatment with CD19-specific CAR T-cell therapy in children, adolescent and young adult patients with B-cell acute lymphoblastic leukemia

CD19-specific chimeric antigen receptor (CAR) T-cell therapy has shown promising disease responses in patients with high-risk B-cell malignancies. Treatment with CD19-CAR T-cell therapy is also associated with the risk of morbidity and mortality, primarily related to immune-mediated complications (c...

Descripción completa

Detalles Bibliográficos
Autores principales: Petgrave, Yonique P, Selukar, Subodh, Epperly, Rebecca, Naik, Swati, Santos, Noel DeLos, Triplett, Brandon M, Gottschalk, Stephen, Bissler, John, Talleur, Aimee C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602103/
https://www.ncbi.nlm.nih.gov/pubmed/37886451
http://dx.doi.org/10.21203/rs.3.rs-3396661/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602103/
https://www.ncbi.nlm.nih.gov/pubmed/37886451
http://dx.doi.org/10.21203/rs.3.rs-3396661/v1

Ejemplares similares